drugset / Trial / NCT00092443

Dose Confirmation Efficacy Study (V260-007)

NCT00092443

Phase 3 Completed 1312 enrolled Merck Sharp & Dohme LLC
RandomizedParallel-groupDouble-blindPrevention

Summary

This study was designed to evaluate the safety of the investigational Rotavirus Vaccine and the efficacy to prevent Rotavirus Gastroenteritis.

Timeline

Start
2002-09
Primary completion
2004-06
Completion
2004-06

Drugs

EvaluationDrugModalityDoseRoute
Subject Rotarix Vaccine 1.1e+07 iu Oral

Indications